Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NOS1 | P29475 | 7/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PAH | P00439 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepiapterin SCHEMBL20374908 | 1.00 | HSD17B10 (1.00) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL7943016 | 1.00 | HSD17B10 (1.00) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL19734024 | 0.91 | CASP7 (0.83) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL20374992 | 0.80 | CASP7 (0.67) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL258399 | 0.79 | CASP7 (0.65) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL27081912 | 0.79 | CASP7 (0.65) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL258405 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL21009255 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL31026287 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL29365035 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122931-A1 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | PTC THERAPEUTICS MP INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240115572-A1 | METHODS FOR TREATING GLIOBLASTOMAS WITH SEPIAPTERIN | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| EP-4291190-A1 | METHODS FOR TREATING GLIOBLASTOMAS WITH SEPIAPTERIN | PTC Therapeutics MP, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4291196-A1 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | PTC Therapeutics MP, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022173834-A1 | METHODS FOR TREATING GLIOBLASTOMAS WITH SEPIAPTERIN | PTC THERAPEUTICS MP, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022173823-A1 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | PTC THERAPEUTICS MP, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3213062-B1 | METHODS AND ASSAYS RELATING TO SEPIAPTERIN REDUCTASE INHIBITION | CHILDRENS MEDICAL CENTER (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10365267-B2 | Methods and assays relating to sepiapterin reductase inhibition | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| EP-2848619-B1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | SHIRATORI PHARMACEUTICAL CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-20170307591-A1 | METHODS AND ASSAYS RELATING TO SEPIAPTERIN REDUCTASE INHIBITION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-9181254-B2 | Method for producing sepiapterin and tetrahydrolactoylpterin | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9181254-B2 | Method for producing sepiapterin and tetrahydrolactoylpterin | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150119574-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2015-04-30 | — | — | US | disclosed |
| US-20150119574-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2848619-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | Shiratori Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-7820667-B2 | Methods of treating hypertension | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820667-B2 | Methods of treating hypertension | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070049599-A1 | Use of bh4 for the treatment of respiratory diseases | ALTANA PHARMA AG (DE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049599-A1 | Use of bh4 for the treatment of respiratory diseases | ALTANA PHARMA AG (DE) | 2007-03-01 | — | — | US | disclosed |
| WO-2005041975-A1 | USE OF BH4 FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049599-A1 | Use of bh4 for the treatment of respiratory diseases | BHMT, BHMT2, PAH | HSD17B10 300/4885CASP7 3145/4885KDM4E 409/4885 |
| US-10365267-B2 | Methods and assays relating to sepiapterin reductase inhibition | SPR, SHMT2, SHMT1 | HSD17B10 62/4885CASP7 2400/4885KDM4E 975/4885 |
| US-20150119574-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | SPR, HPN, RNPEP | HSD17B10 348/4885CASP7 1605/4885KDM4E 4148/4885 |
| US-20170307591-A1 | METHODS AND ASSAYS RELATING TO SEPIAPTERIN REDUCTASE INHIBITION | SPR, SHMT2, SHMT1 | HSD17B10 62/4885CASP7 2400/4885KDM4E 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.